Emergent BioSolutions Inc. has announced a $30 million contract modification awarded by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. The contract is for the supply of CYFENDUS®, an anthrax vaccine approved for post-exposure prophylaxis in individuals aged 18 to 65. Deliveries are set to start this year and be completed by March 2026. This contract follows a previous $50 million modification in December 2024. The vaccine is part of efforts to protect against anthrax, a Tier 1 biological threat.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-25-000183), on September 05, 2025, and is solely responsible for the information contained therein.